Bank now. Expansion makes it useful. The field is real. Your own cells are the safe way in.

How the Evidence Room works: We state a hypothesis, gather the strongest published evidence for and against it, and grade our confidence using a fixed rubric. Every study is cited and linked, limitations included. When the evidence is mixed, we say so. When new evidence changes the picture, we update the verdict and log the change. This is how we'd want the science explained to us.

1. Supported—High confidence

   Your stem cells will never be younger: potency declines with age — and no technology restores it.

   Growth capacity, expansion headroom, and senescence burden decline with donor age. That is what banking and expansion actually depend on.

2. Supported—Moderate-to-High confidence

   Culture-expanded MSCs outperform same-day procedures — because structural outcomes require doses only expansion can reach.

   A typical aspirate yields roughly 0.5–2 million MSCs. Outcomes cluster at 20–100 million cells. That dose is physically unreachable without expansion.

3. Supported—High confidence

   MSC therapy outperforms PRP for degenerative joint and tendon conditions.

   The strongest comparative evidence in the room for culture-expanded MSCs in degenerative joint and tendon disease, including knee osteoarthritis.

4. Supported—High confidence

   Your own cells are the safest cells: autologous MSC therapy minimizes immune risk.

   No donor matching, no alloimmunization, no donor-disease transmission. Allogeneic cells carry a documented donor-specific antibody rate — most relevant for the multi-dose future expansion enables.

Physician? Think we've missed a study — for or against? Tell us: info@foreverlabs.com.